N
35.08
0.34 (0.98%)
| Previous Close | 34.74 |
| Open | 34.78 |
| Volume | 1,049,687 |
| Avg. Volume (3M) | 1,111,006 |
| Market Cap | 3,977,749,504 |
| Price / Sales | 111.67 |
| Price / Book | 5.41 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NewAmsterdam Pharma Company N.V | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2025 | 2,869,565 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (HC Wainwright & Co., 48.23%) | Buy |
| Median | 48.00 (36.83%) | |
| Low | 37.00 (Goldman Sachs, 5.47%) | Hold |
| Average | 46.50 (32.55%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 36.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 16 Dec 2025 | 50.00 (42.53%) | Buy | 34.22 |
| Goldman Sachs | 02 Dec 2025 | 37.00 (5.47%) | Hold | 38.33 |
| RBC Capital | 06 Nov 2025 | 44.00 (25.43%) | Buy | 37.05 |
| Needham | 05 Nov 2025 | 46.00 (31.13%) | Buy | 38.13 |
| HC Wainwright & Co. | 20 Oct 2025 | 52.00 (48.23%) | Buy | 37.66 |
| Citigroup | 17 Oct 2025 | 50.00 (42.53%) | Buy | 36.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Dec 2025 | Announcement | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Nov 2025 | Announcement | NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December |
| 07 Nov 2025 | Announcement | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Nov 2025 | Announcement | NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results |
| 30 Oct 2025 | Announcement | NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November |
| 14 Oct 2025 | Announcement | Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |